

Information for Adults Diagnosed With Lichen Planopilaris

To learn more about the ALPINE Study, or to see if you may qualify, visit alpine-study.com.

You can also contact your local site directly:

757-625-0151

SITE PHONE

drixon@vcrinc.org

SITE EMAIL



The ALPINE Study, a clinical trial of an investigational oral treatment, is now enrolling adults who are living with lichen planopilaris.



What is Lichen Planopilaris (LPP)?

LPP is an inflammatory scalp condition caused by the body's immune response. LPP may cause itching, burning, scarring, and permanent hair loss. These symptoms can worsen over time and impact quality of life. While treatments are available, they can cause serious side effects and may not work for everyone. Researchers continue to develop potential new treatments for people living with LPP.

About the Study

The ALPINE Study is evaluating an investigational oral medicine, called brepocitinib, in adults living with the inflammatory effects of LPP. Brepocitinib is investigational because it is not yet approved for use outside of clinical trials. This study will determine if brepocitinib reduces inflammation in LPP, improves symptoms, and is safe for use in this disease.

Participating in this study is voluntary, and you can choose to leave the study at any time. There is no cost to participate. Compensation for study-related time and

expenses, as well as travel coordination services, may also be available.

Who Can Participate?

You may be eligible to participate in the ALPINE Study if you are at least 18 years old and:

Diagnosed with lichen planopilaris

Have active LPP-related scalp symptoms

Are not currently pregnant, breastfeeding, or planning to become pregnant

Other eligibility criteria apply. The study physician will determine if this study is right for you based on all criteria.

Why Participate?

Clinical trials like the ALPINE Study depend on the participation of patients. By choosing to take part in this study, you will contribute to research that could make a difference for others living with LPP. Thank you for considering this important study.

What to Expect

If you qualify and choose to participate, you will be in the study for a little over 1 year.

This study has 4 periods:

Screening (up to 4 weeks/about 1 month): You will have a series of medical assessments, including a physical exam, ECG, questionnaires, and blood tests.

Blinded Treatment Period (24 weeks/about 6 months): If you qualify for the study, you will take either the investigational medicine, brepocitinib, or a placebo once a day. The placebo is a tablet that looks identical to brepocitinib but does not contain any active ingredients. You will have at least 7 visits to the study center.

Open-Label Extension Period (28 weeks/about 7 months): If you complete the Blinded Treatment Period, and the study doctor confirms you are eligible, you may choose to enter the Open-Label Treatment Period. During this part of the study, all participants will take brepocitinib once a day, and no placebo will be given. You will have at least 4 visits to the study center during this period. **Follow-Up Period (4 weeks/about 1 month):** About 28 days

after your last dose of brepocitinib, you will attend a follow-up appointment with the study physician for final health checks.